Discovery and Development Technologies, Merck Healthcare KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany.
Site Management Analytics, Merck KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany.
ChemMedChem. 2023 Apr 17;18(8):e202200615. doi: 10.1002/cmdc.202200615. Epub 2023 Feb 28.
Herein, we describe a systematic SAR- and SPR-investigation of the peptidomimetic hydroxy-proline based VHL-ligand VH032, from which most to-date published VHL-targeting PROTACs have been derived. This study provides for the first time a consistent data set which allows for direct comparison of structural variations including those which were so far hidden in patent literature. The gained knowledge about improved VHL binders was used to design a small library of highly potent BRD4-degraders comprising different VHL exit vectors. Newly designed degraders showed favorable molecular properties and significantly improved degradation potency compared to MZ1.
在此,我们描述了对基于羟脯氨酸的肽模拟 VHL 配体 VH032 的系统 SAR 和 SPR 研究,迄今为止大多数已发表的 VHL 靶向 PROTAC 均源自于此。该研究首次提供了一致的数据组,可直接比较结构变化,包括迄今为止隐藏在专利文献中的结构变化。关于改进的 VHL 结合物的知识被用于设计一个包含不同 VHL 出口载体的高活性 BRD4 降解物的小型文库。与 MZ1 相比,新设计的降解物显示出更好的分子特性和显著提高的降解效力。